The PTTG1-targeting miRNAs miR-329, miR-300, miR-381, and miR-655 inhibit pituitary tumor cell tumorigenesis and are involved in a p53/PTTG1 regulation feedback loop

Oncotarget

Volumn 6, Issue 30, 2015, Pages 29413-29427

  Liang, Hai Qian ^a   Wang, Ren Jie ^a   Diao, Cai Feng ^b   Li, Jian Wei ^a   Su, Jing Liang ^a   Zhang, Sai ^a  

^a Pingjin Hospital   (China)

^b Tianjin Saier Biological Technology Company   (China)

Author keywords

MiRNAs; P53; Pituitary tumor; PTTG1

Indexed keywords

MESSENGER RNA; MICRORNA; MICRORNA 300; MICRORNA 329; MICRORNA 381; MICRORNA 655; PROTEIN P53; SECURIN; UNCLASSIFIED DRUG; 3' UNTRANSLATED REGION; MIRN300 MICRORNA, HUMAN; MIRN329 MICRORNA, HUMAN; MIRN381 MICRORNA, HUMAN; MIRN655 MICRORNA, HUMAN; PITUITARY TUMOR-TRANSFORMING PROTEIN 1, HUMAN; TP53 PROTEIN, HUMAN;

3' UNTRANSLATED REGION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BINDING SITE; CELL INVASION; CHROMOSOME 14Q; CHROMOSOME 14Q32.21; CONTROLLED STUDY; EXPRESSION VECTOR; FEEDBACK SYSTEM; FEMALE; GENE TARGETING; HYPOPHYSIS TUMOR; MIGRATION INHIBITION; MOUSE; NONHUMAN; PITUITARY TUMOR CELL LINE; PITUITARY TUMOR TRANSFORMING GENE 1; PROMOTER REGION; TRANSCRIPTION INITIATION; UPREGULATION; ANIMAL; CARCINOGENESIS; CELL MOTION; CELL PROLIFERATION; CELL SURVIVAL; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; GENETICS; HUMAN; METABOLISM; NUDE MOUSE; PATHOLOGY; SIGNAL TRANSDUCTION; TIME FACTOR; TUMOR CELL LINE; TUMOR INVASION;

3' UNTRANSLATED REGIONS; ANIMALS; APOPTOSIS; BINDING SITES; CARCINOGENESIS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; FEEDBACK, PHYSIOLOGICAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE, NUDE; MICRORNAS; NEOPLASM INVASIVENESS; PITUITARY NEOPLASMS; SECURIN; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSCRIPTION, GENETIC; TRANSFECTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84945152421     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.5003     Document Type: Article

References (54)

1. Pei L, Melmed S. Isolation and characterization of a pituitary tumor-transforming gene (PTTG). Molecular endocrinology (Baltimore, Md). 1997; 11:433-441.
2. Zou H, McGarry TJ, Bernal T, Kirschner MW. Identification of a vertebrate sister-chromatid separation inhibitor involved in transformation and tumorigenesis. Science. 1999; 285:418-422.
3. Pei L. Pituitary tumor-transforming gene protein associates with ribosomal protein S10 and a novel human homologue of DnaJ in testicular cells. The Journal of biological chemistry. 1999; 274:3151-3158.
4. Filippella M, Galland F, Kujas M, Young J, Faggiano A, Lombardi G, Colao A, Meduri G, Chanson P. Pituitary tumour transforming gene (PTTG) expression correlates with the proliferative activity and recurrence status of pituitary adenomas: a clinical and immunohistochemical study. Clinical endocrinology. 2006; 65:536-543.
5. Zhang X, Horwitz GA, Heaney AP, Nakashima M, Prezant TR, Bronstein MD, Melmed S. Pituitary tumor transforming gene (PTTG) expression in pituitary adenomas. The Journal of clinical endocrinology and metabolism. 1999; 84:761-767.
6. Honda S, Hayashi M, Kobayashi Y, Ishikawa Y, Nakagawa K, Tsuchiya E. A role for the pituitary tumor-transforming gene in the genesis and progression of non-small cell lung carcinomas. Anticancer research. 2003; 23:3775-3782.
7. Heaney AP, Singson R, McCabe CJ, Nelson V, Nakashima M, Melmed S. Expression of pituitary-tumour transforming gene in colorectal tumours. Lancet. 2000; 355:716-719.
8. Cho-Rok J, Yoo J, Jang YJ, Kim S, Chu IS, Yeom YI, Choi JY, Im DS. Adenovirus-mediated transfer of siRNA against PTTG1 inhibits liver cancer cell growth in vitro and in vivo. Hepatology (Baltimore, Md). 2006; 43:1042-1052.
9. Mora-Santos M, Limon-Mortes MC, Giraldez S, HerreroRuiz J, Saez C, Japon MA, Tortolero M, Romero F. Glycogen synthase kinase-3beta (GSK3beta) negatively regulates PTTG1/human securin protein stability, and GSK3beta inactivation correlates with securin accumulation in breast tumors. The Journal of biological chemistry. 2011; 286:30047-30056.
10. Moreno-Mateos MA, Espina AG, Torres B, Gamez del Estal MM, Romero-Franco A, Rios RM, Pintor-Toro JA. PTTG1/securin modulates microtubule nucleation and cell migration. Molecular biology of the cell. 2011; 22:4302-4311.
11. Jallepalli PV, Waizenegger IC, Bunz F, Langer S, Speicher MR, Peters JM, Kinzler KW, Vogelstein B, Lengauer C. Securin is required for chromosomal stability in human cells. Cell. 2001; 105:445-457.
12. Yu R, Heaney AP, Lu W, Chen J, Melmed S. Pituitary tumor transforming gene causes aneuploidy and p53-dependent and p53-independent apoptosis. The Journal of biological chemistry. 2000; 275:36502-36505.
13. Lewy GD, Ryan GA, Read ML, Fong JC, Poole V, Seed RI, Sharma N, Smith VE, Kwan PP, Stewart SL, Bacon A, Warfield A, Franklyn JA, McCabe CJ, Boelaert K. Regulation of pituitary tumor transforming gene (PTTG) expression and phosphorylation in thyroid cells. Endocrinology. 2013; 154:4408-4422.
14. Ishikawa H, Heaney AP, Yu R, Horwitz GA, Melmed S. Human pituitary tumor-transforming gene induces angiogenesis. The Journal of clinical endocrinology and metabolism. 2001; 86:867-874.
15. Kim DS, Franklyn JA, Boelaert K, Eggo MC, Watkinson JC, McCabe CJ. Pituitary tumor transforming gene (PTTG) stimulates thyroid cell proliferation via a vascular endothelial growth factor/kinase insert domain receptor/inhibitor of DNA binding-3 autocrine pathway. The Journal of clinical endocrinology and metabolism. 2006; 91:4603-4611.
16. Tong Y, Eigler T. Transcriptional targets for pituitary tumor-transforming gene-1. Journal of molecular endocrinology. 2009; 43:179-185.
17. Tong Y, Tan Y, Zhou C, Melmed S. Pituitary tumor transforming gene interacts with Sp1 to modulate G1/S cell phase transition. Oncogene. 2007; 26:5596-5605.
18. Bernal JA, Luna R, Espina A, Lazaro I, Ramos-Morales F, Romero F, Arias C, Silva A, Tortolero M, Pintor-Toro JA. Human securin interacts with p53 and modulates p53-mediated transcriptional activity and apoptosis. Nature genetics. 2002; 32:306-311.
19. Hlubek F, Pfeiffer S, Budczies J, Spaderna S, Jung A, Kirchner T, Brabletz T. Securin (hPTTG1) expression is regulated by beta-catenin/TCF in human colorectal carcinoma. British journal of cancer. 2006; 94:1672-1677.
20. Chesnokova V, Zonis S, Wawrowsky K, Tani Y, BenShlomo A, Ljubimov V, Mamelak A, Bannykh S, Melmed S. Clusterin and FOXL2 act concordantly to regulate pituitary gonadotroph adenoma growth. Molecular endocrinology (Baltimore, Md). 2012; 26:2092-2103.
21. Zhou C, Wawrowsky K, Bannykh S, Gutman S, Melmed S. E2F1 induces pituitary tumor transforming gene (PTTG1) expression in human pituitary tumors. Molecular endocrinology (Baltimore, Md). 2009; 23:2000-2012.
22. Alonso MM, Fueyo J, Shay JW, Aldape KD, Jiang H, Lee OH, Johnson DG, Xu J, Kondo Y, Kanzawa T, Kyo S, Bekele BN, Zhou X, Nigro J, McDonald JM, Yung WK, et al. Expression of transcription factor E2F1 and telomerase in glioblastomas: mechanistic linkage and prognostic significance. Journal of the National Cancer Institute. 2005; 97:1589-1600.
23. Lujambio A, Lowe SW. The microcosmos of cancer. Nature. 2012; 482:347-355.
24. Iorio MV, Croce CM. microRNA involvement in human cancer. Carcinogenesis. 2012; 33:1126-1133.
25. Ebert MS, Sharp PA. Roles for microRNAs in conferring robustness to biological processes. Cell. 2012; 149:515-524.
26. Ptashne M. Binding reactions: epigenetic switches, signal transduction and cancer. Current biology: CB. 2009; 19:R234-241.
27. Bisio A, De Sanctis V, Del Vescovo V, Denti MA, Jegga AG, Inga A, Ciribilli Y. Identification of new p53 target microRNAs by bioinformatics and functional analysis. BMC cancer. 2013; 13:552.
28. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature. 2000; 408:307-310.
29. Idogawa M, Ohashi T, Sasaki Y, Maruyama R, Kashima L, Suzuki H, Tokino T. Identification and analysis of large intergenic non-coding RNAs regulated by p53 family members through a genome-wide analysis of p53-binding sites. Human molecular genetics. 2014; 23:2847-2857.
30. Hunten S, Siemens H, Kaller M, Hermeking H. The p53/microRNA network in cancer: experimental and bioinformatics approaches. Advances in experimental medicine and biology. 2013; 774:77-101.
31. Corney DC, Flesken-Nikitin A, Godwin AK, Wang W, Nikitin AY. MicroRNA-34b and MicroRNA-34c are targets of p53 and cooperate in control of cell proliferation and adhesion-independent growth. Cancer research. 2007; 67:8433-8438.
32. Formosa A, Markert EK, Lena AM, Italiano D, Finazzi-Agro E, Levine AJ, Bernardini S, Garabadgiu AV, Melino G, Candi E. MicroRNAs, miR-154, miR-299-5p, miR-376a, miR-376c, miR-377, miR-381, miR-487b, miR-485-3p, miR-495 and miR-654-3p, mapped to the 14q32.31 locus, regulate proliferation, apoptosis, migration and invasion in metastatic prostate cancer cells. Oncogene. 2014; 33:5173-5182.
33. Jia W, Lu R, Jia G, Ni M, Xu Z. Expression of pituitary tumor transforming gene (PTTG) in human pituitary macroadenomas. Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine. 2013; 34:1559-1567.
34. Mete O, Ezzat S, Asa SL. Biomarkers of aggressive pituitary adenomas. Journal of molecular endocrinology. 2012; 49:R69-78.
35. Gadelha MR, Trivellin G, Hernandez Ramirez LC, Korbonits M. Genetics of pituitary adenomas. Frontiers of hormone research. 2013; 41:111-140.
36. Wondergem B, Zhang Z, Huang D, Ong CK, Koeman J, Hof DV, Petillo D, Ooi A, Anema J, Lane B, Kahnoski RJ, Furge KA, Teh BT. Expression of the PTTG1 oncogene is associated with aggressive clear cell renal cell carcinoma. Cancer research. 2012; 72:4361-4371.
37. Liao YC, Ruan JW, Lua I, Li MH, Chen WL, Wang JR, Kao RH, Chen JH. Overexpressed hPTTG1 promotes breast cancer cell invasion and metastasis by regulating GEF-H1/RhoA signalling. Oncogene. 2012; 31:3086-3097.
38. Mu YM, Oba K, Yanase T, Ito T, Ashida K, Goto K, Morinaga H, Ikuyama S, Takayanagi R, Nawata H. Human pituitary tumor transforming gene (hPTTG) inhibits human lung cancer A549 cell growth through activation of p21(WAF1/CIP1). Endocrine journal. 2003; 50:771-781.
39. Liang M, Chen X, Liu W, Li S, Li C, Jiang L, Lv S. Role of the pituitary tumor transforming gene 1 in the progression of hepatocellular carcinoma. Cancer Biology & Therapy. 2014; 11:337-345.
40. Hatcher RJ, Dong J, Liu S, Bian G, Contreras A, Wang T, Hilsenbeck SG, Li Y, Zhang P. Pttg1/securin is required for the branching morphogenesis of the mammary gland and suppresses mammary tumorigenesis. Proceedings of the National Academy of Sciences of the United States of America. 2014; 111:1008-1013.
41. Xiao B, Tan L, He B, Liu Z, Xu R. MiRNA-329 targeting E2F1 inhibits cell proliferation in glioma cells. Journal of translational medicine. 2013; 11:172.
42. Chen B, Duan L, Yin G, Tan J, Jiang X. Simultaneously expressed miR-424 and miR-381 synergistically suppress the proliferation and survival of renal cancer cells-Cdc2 activity is up-regulated by targeting WEE1. Clinics. 2013; 68:825-833.
43. Wang Y, Zang W, Du Y, Ma Y, Li M, Li P, Chen X, Wang T, Dong Z, Zhao G. Mir-655 up-regulation suppresses cell invasion by targeting pituitary tumor-transforming gene-1 in esophageal squamous cell carcinoma. Journal of translational medicine. 2013; 11:301.
44. Formosa A, Lena AM, Markert EK, Cortelli S, Miano R, Mauriello A, Croce N, Vandesompele J, Mestdagh P, Finazzi-Agro E, Levine AJ, Melino G, Bernardini S, Candi E. DNA methylation silences miR-1 in prostate cancer. Oncogene. 2013; 32:127-134.
45. Kuriyama M, Obata K, Miyagawa Y, Nishikawa E, Koide T, Takeda A, Komeda Y, Kanbayashi T, Nakano M, Miyake K. Serum prostate-specific antigen values for the prediction of clinical stage and prognosis in patients with prostate cancer: an analysis of 749 cases. International journal of urology: official journal of the Japanese Urological Association. 1996; 3:462-467.
46. Zehavi L, Avraham R, Barzilai A, Bar-Ilan D, Navon R, Sidi Y, Avni D, Leibowitz-Amit R. Silencing of a large microRNA cluster on human chromosome 14q32 in melanoma: biological effects of mir-376a and mir-376c on insulin growth factor 1 receptor. Molecular cancer. 2012; 11:44.
47. Costa FF, Bischof JM, Vanin EF, Lulla RR, Wang M, Sredni ST, Rajaram V, Bonaldo Mde F, Wang D, Goldman S, Tomita T, Soares MB. Identification of microRNAs as potential prognostic markers in ependymoma. PloS one. 2011; 6:e25114.
48. Gattolliat CH, Thomas L, Ciafre SA, Meurice G, Le Teuff G, Job B, Richon C, Combaret V, Dessen P, Valteau-Couanet D, May E, Busson P, Douc-Rasy S, Benard J. Expression of miR-487b and miR-410 encoded by 14q32.31 locus is a prognostic marker in neuroblastoma. British journal of cancer. 2011; 105:1352-1361.
49. Haller F, von Heydebreck A, Zhang JD, Gunawan B, Langer C, Ramadori G, Wiemann S, Sahin O. Localizationand mutation-dependent microRNA (miRNA) expression signatures in gastrointestinal stromal tumours (GISTs), with a cluster of co-expressed miRNAs located at 14q32.31. The Journal of pathology. 2010; 220:71-86.
50. Lavon I, Zrihan D, Granit A, Einstein O, Fainstein N, Cohen MA, Cohen MA, Zelikovitch B, Shoshan Y, Spektor S, Reubinoff BE, Felig Y, Gerlitz O, Ben-Hur T, Smith Y, Siegal T. Gliomas display a microRNA expression profile reminiscent of neural precursor cells. Neuro-oncology. 2010; 12:422-433.
51. Barlev NA, Sayan BS, Candi E, Okorokov AL. The microRNA and p53 families join forces against cancer. Cell death and differentiation. 2010; 17:373-375.
52. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, Antipin Y, Reva B, Goldberg AP, Sander C, Schultz N. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer discovery. 2012; 2:401-404.
53. Soussi T. TP53 mutations in human cancer: database reassessment and prospects for the next decade. Advances in cancer research. 2011; 110:107-139.
54. Zhou Y, Mehta KR, Choi AP, Scolavino S, Zhang X. DNA damage-induced inhibition of securin expression is mediated by p53. The Journal of biological chemistry. 2003; 278:462-470.